Prolactinoma is a type of pituitary tumour that produces an excessive amount of the hormone prolactin. It is the most common type of hormonally-active pituitary tumour. These tumours can cause ocular complications such as vision loss and visual fields (VF) defect. In this study, we aimed to evaluate the thickness of chorioretinal layers in patients with prolactinoma.
We enrolled 63 eyes of 32 prolactinoma patients and 36 eyes of 18 age and gender-matched healthy controls. All participants underwent complete hormonal and ophthalmological examination, including spectral-domain optical coherence tomography (SD-OCT) and VF test.The complete biochemical response was defined as serum PRL concentration ≤ 20 ng/mL at the time of evaluation.The seven layers were retinal nerve fibre layer (RNFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL), and retinal pigment epithelium (RPE). The results of prolactinoma patients were compared with the control group.
The mean RNFL, GCL, IPL, INL, ONL, and RPE were thinner in prolactinoma patients than the control group (p < 0.05) while OPL was similar between groups (p > 0.05).None of the patients had VF defect.The thickness of retinal layers was similar in patients with and without complete biochemical response (p > 0.05).
To our knowledge, this is the first study that evaluates the thickness of chorioretinal layers in patients with prolactinoma.Most of the layers were thinner than the control group.Therefore, detailed eye assessment should be a routine component of the follow-up visits of prolactinoma patients and further studies related to this condition are required.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Miyai K, Ichihara K, Kondo K, Mori S (1986) Asymptomatic hyperprolactinaemia and prolactinoma in the general population–mass screening by paired assays of serum prolactin. Clin Endocrinol (Oxf) 25(5):549–554
Glezer A, Bronstein MD (2015) Prolactinomas. Endocrinol Metab Clin North Am 44(1):71–78. https://doi.org/10.1016/j.ecl.2014.11.003
Dollar JR, Blackwell RE (1986) Diagnosis and management of prolactinomas. Cancer Metastasis Rev 5(2):125–138
Ciccarelli A, Daly AF, Beckers A (2005) The epidemiology of prolactinomas. Pituitary 8(1):3–6. https://doi.org/10.1007/s11102-005-5079-0
Mann WA (2011) Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach. Eur J Clin Invest 41(3):334–342. https://doi.org/10.1111/j.1365-2362.2010.02399.x
Mah PM, Webster J (2002) Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med 20(4):365–374. https://doi.org/10.1055/s-2002-36709
Asano S, Ueki K, Suzuki I, Kirino T (2001) Clinical features and medical treatment of male prolactinomas. Acta Neurochir (Wien) 143(5):465–470
Nomikos P, Buchfelder M, Fahlbusch R (2001) Current management of prolactinomas. J Neurooncol 54(2):139–150
Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65(2):265–273. https://doi.org/10.1111/j.1365-2265.2006.02562.x
Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, Hee MR, Flotte T, Gregory K, Puliafito CA et al (1991) Optical coherence tomography. Science 254(5035):1178–1181
Drexler W, Fujimoto JG (2008) State-of-the-art retinal optical coherence tomography. Prog Retin Eye Res 27(1):45–88. https://doi.org/10.1016/j.preteyeres.2007.07.005
Sun JK, Lin MM, Lammer J, Prager S, Sarangi R, Silva PS, Aiello LP (2014) Disorganisation of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol 132(11):1309–1316. https://doi.org/10.1001/jamaophthalmol.2014.2350
Invernizzi A, Pellegrini M, Acquistapace A, Benatti E, Erba S, Cozzi M, Cigada M, Viola F, Gillies M, Staurenghi G (2018) Normative data for retinal-layer thickness maps generated by spectral-domain OCT in a white population. Ophthalmol Retina 2 (8):808–815 e801. https://doi.org/10.1016/j.oret.2017.12.012
Staurenghi G, Sadda S, Chakravarthy U, Spaide RF, International Nomenclature for Optical Coherence Tomography P (2014) Proposed lexicon for anatomic landmarks in normal posterior segment spectral-domain optical coherence tomography: the IN*OCT consensus. Ophthalmology 121(8):1572–1578. https://doi.org/10.1016/j.ophtha.2014.02.023
Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group (1985). Arch Ophthalmol 103 (12):1796–1806
Ikeda H, Yoshimoto T (1995) Visual disturbances in patients with pituitary adenoma. Acta Neurol Scand 92(2):157–160
Bergland R (1969) The arterial supply of the human optic chiasm. J Neurosurg 31(3):327–334. https://doi.org/10.3171/jns.1969.31.3.0327
McIlwaine GG, Carrim ZI, Lueck CJ, Chrisp TM (2005) A mechanical theory to account for bitemporal hemianopia from chiasmal compression. J Neuroophthalmol 25(1):40–43
Jacob M, Raverot G, Jouanneau E, Borson-Chazot F, Perrin G, Rabilloud M, Tilikete C, Bernard M, Vighetto A (2009) Predicting visual outcome after treatment of pituitary adenomas with optical coherence tomography. Am J Ophthalmol 147 (1):64–70 e62. https://doi.org/10.1016/j.ajo.2008.07.016
Monteiro ML, Costa-Cunha LV, Cunha LP, Malta RF (2010) Correlation between macular and retinal nerve fibre layer Fourier-domain OCT measurements and visual field loss in chiasmal compression. Eye (Lond) 24(8):1382–1390. https://doi.org/10.1038/eye.2010.48
Moon CH, Hwang SC, Kim BT, Ohn YH, Park TK (2011) Visual prognostic value of optical coherence tomography and photopic negative response in chiasmal compression. Invest Ophthalmol Vis Sci 52(11):8527–8533. https://doi.org/10.1167/iovs.11-8034
Danesh-Meyer HV, Carroll SC, Foroozan R, Savino PJ, Fan J, Jiang Y, Vander Hoorn S (2006) Relationship between retinal nerve fiber layer and visual field sensitivity as measured by optical coherence tomography in chiasmal compression. Invest Ophthalmol Vis Sci 47(11):4827–4835. https://doi.org/10.1167/iovs.06-0327
Duru N, Ersoy R, Altinkaynak H, Duru Z, Cagil N, Cakir B (2016) Evaluation of retinal nerve fiber layer thickness in acromegalic patients using spectral-domain optical coherence tomography. Semin Ophthalmol 31(3):285–290. https://doi.org/10.3109/08820538.2014.962165
Djamgoz MB, Hankins MW, Hirano J, Archer SN (1997) Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Res 37(24):3509–3529. https://doi.org/10.1016/S0042-6989(97)00129-6
RL R (2005) Visual function in Parkinson’s disease. In: Ebadi MPR (ed) Parkinson’s disease, 1st edn. Sigma, Turkey, pp 229–236
Harnois C, Di Paolo T (1990) Decreased dopamine in the retinas of patients with Parkinson’s disease. Invest Ophthalmol Vis Sci 31(11):2473–2475
Bodis-Wollner I (1990) Visual deficits related to dopamine deficiency in experimental animals and Parkinson’s disease patients. Trends Neurosci 13(7):296–302
Lewis MM, Huang X, Nichols DE, Mailman RB (2006) D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson’s disease. CNS Neurol Disord Drug Targets 5(3):345–353
Jackson GR, Owsley C (2003) Visual dysfunction, neurodegenerative diseases, and aging. Neurol Clin 21(3):709–728
Yavas GF, Yilmaz O, Kusbeci T, Ozturk F (2007) The effect of levodopa and dopamine agonists on optic nerve head in Parkinson disease. Eur J Ophthalmol 17(5):812–816
Sink M, Chou J (2012) Prolactinomas and the eye: a clinical case and review. Optom Vis Sci 89(11):e85-94. https://doi.org/10.1097/OPX.0b013e31826b094b
Raverot G, Jacob M, Jouanneau E, Delemer B, Vighetto A, Pugeat M, Borson-Chazot F (2009) Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma. Clin Endocrinol (Oxf) 70(4):588–592. https://doi.org/10.1111/j.1365-2265.2008.03364.x
Chuman H, Cornblath WT, Trobe JD, Gebarski SS (2002) Delayed visual loss following pergolide treatment of a prolactinoma. J Neuroophthalmol 22(2):102–106
This research received no specific grant from any funding agency in the public, commercial, or not for profit sectors.
Conflicts of interest
The authors report no conflicts of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ogmen, B.E., Ugurlu, N., Faki, S. et al. Retinal layers in prolactinoma patients: a spectral-domain optical coherence tomography study. Int Ophthalmol (2021). https://doi.org/10.1007/s10792-021-01701-8
- Spectral-domain optical coherence tomography (SD-OCT)
- The retinal nerve fibre layer (RNFL)
- Retinal layers
- Ocular disease